Dr. Matthew Johnson will lead research to look at the science and efficacy of MYCO-001 for the treatment of smoking cessation and nicotine dependence DENVER, Sept. 07, 2021 (GLOBE NEWSWIRE) — Mydecine Innovations Group (NEO:MYCO) (OTC:MYCOF) (FSE:0NFA), a biopharmaceutical company focused on the treatment of mental health and addiction, announced it has partnered with Principal Investigator Dr.


Previous articlePT261 – Dr. Tiago Reis Marques – Ketamine, New Drugs, and the Repurposing of Current Drugs
Next articleGlutamate’s Role in Rapidly-Acting Antidepressants